Mesoblast Ltd ADR (MESO) Stock Price, Quote & News

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9639 6036

Fax: 61 3 9639 6030

Website: www.mesoblast.com

Address:

55 Collins Street, Level 38, Melbourne, Australia

Night_Owl_Biotech Jun. 27 at 6:35 PM

The FDA approved $VRDN 's Lumvoa for TED yesterday. Some say it is a minimal threat to $AMGN Tepezza yet the 9 analysts who provide FY30 revenue estimates forecast $850MM to $1.8B in product revenues. VRDN pays 7.5% to DRI Healthcare. The attachment compares VRDN multiples to peer new commercial-stage non-oncology focused bios with 1st approvals over the last 12 months. Only $MESO trades at a lower multiple but there are only multiple analysts providing estimates after FY28. $CYTK & $ARWR are clearly the multiples to aspire to. The multiples may appear high but remember ACLX, NUVL & TERN. This is not investment advice as the comps may be apples to bowling balls.

1 · Reply

BrianRix Jun. 26 at 2:24 PM

$MESO Falling due to EMA rejecting $OMER ? Sick!

0 · Reply

ShadowNick Jun. 6 at 1:06 PM

$MESO Trailing twelve-month revenue exceeded $65 million, up more than 1,000% year-over-year””

0 · Reply

Ninicky May. 29 at 2:27 PM

$MESO looks like a future champion,anyone knows another bargain in biotech,pharma with cl phae 3 candidates? Thx in advance

2 · Reply

trichomy May. 7 at 1:43 PM

$INMB $INMB $KRYS $MESO $NVAX $MRNA There is NO reason why InmuneBio is less than $ 3 right now It is trading at 1.5 right now . Fire sale!!

0 · Reply

trichomy May. 6 at 4:40 PM

$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥

2 · Reply

trichomy May. 5 at 9:38 PM

$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html

1 · Reply

BrianRix May. 1 at 11:49 AM

$MESO back to 20s where we belong

0 · Reply

AlertsAndNews Apr. 30 at 2:42 AM

$MESO headline after the AH close. Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

0 · Reply

ClassiTrader Apr. 30 at 12:59 AM

$MESO Mesoblast reported fiscal third-quarter net revenue from Ryoncil of US$30.3 million on gross sales of US$35.3 million. Net operating cash spend narrowed to US$4.1 million, supported by receipts of US$34.6 million. Cash on hand totaled US$122 million at March 31, 2026. Patient recruitment target was reached in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain. Exclusive worldwide license was secured for patented CAR technology platform to develop precision-enhanced MSC products.

0 · Reply

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

2026-06-18T07:47:02.000Z - 10 days ago

ASX 200 Climbs as Biotech and Mining Stocks Lead Gainers on June 18, 2026

Jun 1, 2026, 6:00 PM EDT - 27 days ago

Mesoblast Slides: Investor presentation

2026-04-30T05:57:05.000Z - 2 months ago

Mesoblast (MESO) Reports Strong Q1 Sales for RyoncilÂ®

Apr 29, 2026, 8:55 PM EDT - 2 months ago

Market Cap	1.71B
Revenue (ttm)	17.20M
Net Income (ttm)	-102.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.84%
Debt to Equity Ratio	0.22

Volume	421,600
Avg Vol	176,360
Day's Range	N/A - N/A
Shares Out	129.46M
Stochastic %K	5%
Beta	2.05
Analysts	Strong Sell
Price Target	$35.00